William Blair Issues Pessimistic Outlook for USPH Earnings

Key Points

• William Blair has reduced its Q3 2025 earnings estimate for U.S. Physical Therapy from $0.70 to $0.68 per share, while also projecting FY2025 earnings at $2.45 EPS.
• Despite the earnings downgrade, analysts remain largely positive, with a consensus rating of "Moderate Buy" and an average price target of $110.25 for the stock.
• U.S. Physical Therapy announced a quarterly dividend of $0.45 per share, reflecting an annual yield of 2.0% and a payout ratio of 78.60%.

U.S. Physical Therapy, Inc. (NYSE:USPH - Free Report) - Analysts at William Blair decreased their Q3 2025 earnings per share estimates for U.S. Physical Therapy in a research report issued on Monday, August 11th. William Blair analyst J. Haase now expects that the company will post earnings of $0.68 per share for the quarter, down from their previous forecast of $0.70. The consensus estimate for U.S. Physical Therapy's current full-year earnings is $2.67 per share. William Blair also issued estimates for U.S. Physical Therapy's FY2025 earnings at $2.45 EPS and FY2027 earnings at $3.23 EPS.

U.S. Physical Therapy (NYSE:USPH - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.10. U.S. Physical Therapy had a return on equity of 8.78% and a net margin of 5.05%. The company had revenue of $197.34 million for the quarter, compared to analysts' expectations of $190.24 million. During the same period in the previous year, the firm posted $0.73 earnings per share. The firm's revenue for the quarter was up 18.0% on a year-over-year basis.

USPH has been the topic of a number of other research reports. Barrington Research upped their target price on U.S. Physical Therapy from $98.00 to $103.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Zacks Research upgraded U.S. Physical Therapy to a "hold" rating in a report on Friday, August 8th. Wall Street Zen raised U.S. Physical Therapy from a "sell" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, JMP Securities restated a "market outperform" rating and set a $113.00 target price on shares of U.S. Physical Therapy in a research report on Tuesday, April 22nd. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, U.S. Physical Therapy currently has an average rating of "Moderate Buy" and an average target price of $110.25.

U.S. Physical Therapy Trading Down 1.5%

Shares of USPH traded down $1.25 during mid-day trading on Thursday, reaching $84.53. 160,977 shares of the company's stock traded hands, compared to its average volume of 144,990. The stock has a market cap of $1.28 billion, a P/E ratio of 36.91, a P/E/G ratio of 4.38 and a beta of 1.45. The stock's 50-day moving average is $77.56 and its two-hundred day moving average is $76.87. U.S. Physical Therapy has a 12 month low of $62.77 and a 12 month high of $101.19. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.18 and a quick ratio of 1.18.

U.S. Physical Therapy Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 22nd will be paid a $0.45 dividend. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $1.80 dividend on an annualized basis and a yield of 2.1%. U.S. Physical Therapy's dividend payout ratio (DPR) is currently 78.60%.

Insider Transactions at U.S. Physical Therapy

In related news, COO Graham D. Reeve sold 1,792 shares of the firm's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $86.57, for a total value of $155,133.44. Following the transaction, the chief operating officer directly owned 22,246 shares of the company's stock, valued at approximately $1,925,836.22. This trade represents a 7.45% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Nancy Ham sold 400 shares of the firm's stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $78.01, for a total transaction of $31,204.00. Following the completion of the transaction, the director directly owned 2,594 shares in the company, valued at $202,357.94. This represents a 13.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.00% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new stake in shares of U.S. Physical Therapy during the 4th quarter valued at approximately $18,886,000. Nuveen LLC purchased a new stake in shares of U.S. Physical Therapy during the 1st quarter valued at approximately $8,702,000. Bahl & Gaynor Inc. raised its position in shares of U.S. Physical Therapy by 32.6% during the 1st quarter. Bahl & Gaynor Inc. now owns 345,003 shares of the company's stock valued at $24,964,000 after buying an additional 84,878 shares during the period. Copeland Capital Management LLC raised its position in shares of U.S. Physical Therapy by 8.9% during the 2nd quarter. Copeland Capital Management LLC now owns 888,735 shares of the company's stock valued at $69,499,000 after buying an additional 72,463 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of U.S. Physical Therapy during the 4th quarter valued at approximately $6,240,000.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.